Compare FDX & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDX | REGN |
|---|---|---|
| Founded | 1971 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.7B | 79.4B |
| IPO Year | N/A | 1991 |
| Metric | FDX | REGN |
|---|---|---|
| Price | $374.18 | $798.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 23 |
| Target Price | $334.57 | ★ $812.57 |
| AVG Volume (30 Days) | ★ 2.1M | 885.1K |
| Earning Date | 03-19-2026 | 01-30-2026 |
| Dividend Yield | ★ 1.55% | 0.47% |
| EPS Growth | ★ 15.62 | 8.19 |
| EPS | 18.14 | ★ 41.48 |
| Revenue | ★ $90,093,000,000.00 | $14,342,900,000.00 |
| Revenue This Year | $6.34 | $11.69 |
| Revenue Next Year | $4.33 | $10.12 |
| P/E Ratio | $20.65 | ★ $19.36 |
| Revenue Growth | ★ 3.09 | 0.99 |
| 52 Week Low | $194.30 | $476.49 |
| 52 Week High | $380.86 | $821.11 |
| Indicator | FDX | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 82.49 | 61.57 |
| Support Level | $362.41 | $745.07 |
| Resistance Level | $380.86 | $790.00 |
| Average True Range (ATR) | 9.75 | 24.14 |
| MACD | 2.83 | 3.45 |
| Stochastic Oscillator | 92.03 | 95.97 |
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In fiscal 2025, the firm's Federal Express segment-which houses the core package delivery operations-made up 86% of total revenue, with 10% coming from FedEx Freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).